5 Minutes With….Manesh R. Patel, MD
Welcome back to MedscapeLIVE! Cardiology E-News! Don’t miss your chance to attend the 2026 HOC at the Fontainebleau Miami at the end of this month—click here to register.
“At the 2026 HOC, I’m looking forward to refreshing myself on some key fundamentals of cardiovascular care – like use of guideline-directed medical therapy in heart failure and updates in antiplatelet therapy for CAD and PAD. But I’m also excited for sessions focused on cutting edge clinical topics – like the role of Lp(a) and emerging therapeutics, when to use genetic testing, and how I should be integrating AI into my clinical practice!” –Dr. Geoffrey Barnes, HOC Advisory Chair
This month we’re joined by Dr. Manesh Patel, HOC Co-Chair. He is the Dr. Richard Sean Stack, MD Distinguished Professor, Professor of Medicine, Chief, Division of Clinical Pharmacology, and Chief, Division of Cardiology, Duke University School of Medicine. Dr. Patel is also Co-Chair of the upcoming Heart of Cardiology meeting. Dr. Patel is involved in several clinical trials involving patients with cardiovascular disease and in cardiac imaging and Chair of the ACC Task Force for Appropriate Use Criteria for Cardiovascular Procedures and is Chair of the AHA Diagnostic and Interventional Cath Committee.
Dr. Patel spoke with us about:
- What he’s most looking forward to at HOC2026
- What’s new in in his research on progress and adoption of ML and AI tools in medicine
- His research grant 1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)
- His article on The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma
- Debates at the upcoming Heart of Cardiology meeting…Think AI, anticoagulation for atrial fibrillation, CT screening for CAD… and more!
Make sure to also check out this issue’s Pulse below, with articles from the Journal of the American Heart Association, Circulation, European Heart Journal, Medscape MedNews, Journal of the American College of Cardiology, Cardiology News, and the New England Journal of Medicine.
CME—It’s not too late!
Going Back to the Heart of Cardiology Medscape Conference (6th Annual)
January 30-February 1, 2026: Fontainebleau Miami Beach Hotel, Miami, Florida
- Earn up to 12.5 CME/CE credits
- View Agenda
- To register, click here!
Thank you to Dr. Patel for sharing his time and expertise! Please contact me at colleen@cmhadvisors.com with any comments and/or suggestions! –Colleen Hutchinson
5 Minutes With….Manesh Patel, MD
Dr. Manesh R. Patel is the Dr. Richard Sean Stack, MD Distinguished Professor, Professor of Medicine, Chief, Division of Clinical Pharmacology, Chief, Division of Cardiology, Core Faculty in Innovation and Entrepreneurship, Member of the Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
What do clinicians need the most guidance on now in cardiology and how does the HOC2026 provide direction?
Dr. Patel: The field is moving so fast with science in cardiology doubling every 70-80 days. At the same time, there is a real opportunity to personalize care and use new emerging tools. HOC2026 is a great review of the major areas of clinical care with updates on the evolving science and practical ways to apply them to your patient care.
Are there any specific presentations you especially look forward to at HOC2026?
Dr. Patel: To be honest, I am really looking forward to Cases and Cocktails (Night One Cases Over Cocktails: My Hardest Patient Decisions/Cases From the Last Year), Great Cardiology Debates, and the All Things Atherosclerosis Showdown. Those will be fun events with lots of interaction!
What are some legitimate debates you currently see evolving in cardiology that may be covered at the HOC 2026 meeting?
Dr. Patel: I think the debates around precision management versus population strategies for individual patients will be key. I mean specifically debates around anticoagulation for atrial fibrillation, computed tomography screening for CAD, and how use of different risk estimates in the age of more data will really push our field forward.
In your recent JAMA Viewpoint article, Translating AI for the Clinician, you state: “We believe that the progress and adoption of ML and AI tools in medicine will be accelerated by a clinical framework for AI development and testing that links evidence generation to indication and benefit and risk and allows clinicians to immediately understand in the context of existing practice guidelines.” What does this mean for clinicians today?
Dr. Patel: Specifically, we think agents and algorithms need indications, evidence generation, and graded levels of evidence for use. You could imagine much like a package label—we have this type of evidence with guideline links so that clinicians and patients can immediately see the value and evidence behind AI generated risk scores, tools to improve health, and potentially predictive models that change our behavior and care to ensure improved outcomes.
Can you tell us a bit about the research grant 1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)—your goals and how is it going?
Dr. Patel: We are trying to determine if an early TEVAR strategy with medical therapy is superior to optimal medical therapy (OMT) for type B uncomplicated aortic dissection. This is a tremendous endeavor with 60 sites in the US - funded by the NIH. We are blessed to have a great team, great principal investigators (PIs) that I work with that help us do this important research.
You are a coauthor on The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. The Lancet article states: “This Commission advocates for a shift in the conceptual framework of coronary artery disease.” Do you have enough support for this, and if so, what is the estimated trajectory and timeline for the Commission’s goals and initiatives?
Dr. Patel: The key to the concepts the Lancet commission discussed is the shift from thinking about ischemia to the total burden of atherosclerosis. This highlights the need to move from treatment to prevention. In fact, we are engaged in the commission of discussing the burden of disease that we can potentially interrupt in the next 20 years targeted therapies for the total atheroma burden for our patients and communities will lead to improved outcomes.
In your recent American Journal of Preventive Cardiology publication, Generalizability of VICTORION-1 PREVENT enrollment criteria to the United States population, what are some takeaways?
Dr. Patel: The Victorian-1 trial aims to demonstrate the effect of primary prevention treatment with inclisiran to reduce cardiovascular outcomes. This study shows that a large part of the population in the United States would meet criteria for enrollment into the study. Given these findings, we believe the trial will be broadly applicable to many patients in the US.
Don’t miss out!
Going Back to the Heart of Cardiology | January 30 - February 1, 2026 | Miami, FL | Register today for 40% OFF with code HOC40
Last chance to register! Don’t miss the 6th Annual Going Back to the Heart of Cardiology Conference taking place January 30 – February 1, 2026 at the Fontainebleau Miami Beach. This three-day CME/CE event will explore the latest advancements in cardiology. In addition to educational sessions, there will be informative bonus presentations, an exhibit and poster hall and networking opportunities. We have gathered a tremendous group of renowned faculty who are excited to bring you the latest advancements in cardiology. You're invited to take advantage of a special 40% OFF discount! Simply use the code HOC40 at checkout. Register Now!
The Pulse
JAHA Original Research: When Less Is More: Is It Time for a New Gold Standard?
NEJM Quick Take: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes
Medical Intelligence Quiz: Coffee consumption and heart failure
Medscape Medical News MedBrief: Semaglutide Tied to Fewer Hospitalizations in Heart Patients
Loading ...